ArticleResearch square2025
Interpretable Multiple Instance Learning for Hematologic Diagnosis from Peripheral Blood Smears.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
41 authors.
Funding
Abstract
Accurate diagnosis of hematologic malignancies from peripheral blood smears (PBSs) requires integrating cellular morphology and composition across hundreds of white blood cells. Existing approaches primarily automate single-cell classification and do not provide whole-slide diagnostic predictions. We present a full network that utilizes a highly performative cell-based encoder (DeepHeme) for feature extraction paired with our weakly supervised framework using attention-based multiple instance learning (MIL) that we call CAREMIL (Cell AggRegation, Explainable, Multiple Instance Learning). Upon evaluating various popular image encoders and MIL architectures, the combination of DeepHeme and CAREMIL is the best performing pipeline on our disease classification task. CAREMIL proves to be a robust aggregation function that outperforms the most commonly used slide level aggregation function (gated multiple instance learning) across several encoder types. The greatest improvements in performance gain with CAREMIL is observed when using out-of-domain encoders, including an encoder trained on ImageNet and leading open-source pathology foundational models (UNI2 and Virchow2). CAREMIL plus DeepHeme achieves the highest diagnostic performance across acute leukemia (AML), myelodysplastic syndromes (MDS), and hairy cell leukemia (HCL) (AUROCs 0.999, 0.891, and 0.945, respectively), and identifies AML disease even in cases with minimal or absent circulating blasts. Attention values assigned by CAREMIL highlight diagnostically relevant cells and reveal disease-specific morphometric signatures, enabling biological interpretability and case-level insight. CAREMIL remains robust to misclassified cell types by the cell image encoder and does not require explicit cell-level supervision. These findings position CAREMIL as an effective and interpretable multiple instance learning framework for hematologic slide diagnosis, with potential to extend to bone marrow aspirates, cytology, and other liquid biopsy specimens, and to support a broader shift toward quantitative, morphology-informed diagnostics in hematology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.